Achieve Life Sciences, Inc. (ACHV) Stock
Healthcare · Biotechnology · CA
$4.95
+2.91%
Last updated Jun 18, 2026 23:57 UTC
ACHV Key Statistics
Market Cap$263.54M
P/E (TTM)-3.81
P/S (TTM)—
P/B (TTM)12.26
Revenue (TTM)$0.00
EPS (TTM)$-1.30
Dividend Yield—
ROE (TTM)-204.14%
Net Margin0.00%
Gross Margin0.00%
52W High$5.25
52W Low$2.62
Analyst ViewBuy
Price Target$4.75
Employees25
Volume67,751
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
CEO: Richard A. Stewart. Company website
See ACHV live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ACHV in Terminal See plans